News Press Releases

42 Biggest Movers From Yesterday

BEBE, VIRX, TCCO, AVXL, MARA, BYON | December 12, 2017

Gainers

Yield10 Bioscience Inc (NASDAQ: YTEN) shares jumped 183.59 percent to close at $5.53 on Monday after the company reported granting of research license to Monsanto for evaluation of 2 novel yield traits in soybean.
ARGENX SE/S ADR (NASDAQ: ARGX) shares climbed 78.88 percent to close at $54.47 after the company reported positive topline results from Phase 2 proof-of-concept trial of ARGX-113 in generalized myasthenia gravis.
Seven Stars Cloud Group Inc (NASDAQ: SSC) shares surged 47.35 percent to close at $3.61 on Monday.
Riot Blockchain Inc (NASDAQ: RIOT) shares climbed 45.52 percent to close at $23.08 on Monday after gaining 8.63 percent on Friday.
Marathon Patent Group Inc (NASDAQ: MARA) shares rose 42.86 percent to close at $6.30 on Monday after declining 3.71 percent on Friday.
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) jumped 38.71 percent to close at $3.44. Wells Fargo upgraded Sunesis Pharmaceuticals from Market Perform to Outperform.
U.S. Global Investors, Inc. (NASDAQ: GROW) shares jumped 35.02 percent to close at $5.33.
Net Element Inc (NASDAQ: NETE) shares surged 34.99 percent to close at $5.44 on Monday.
Arcimoto Inc (NASDAQ: FUV) shares rose 33.83 percent to close at $3.60.
Famous Dave's of America, Inc. (NASDAQ: DAVE) shares climbed 32.08 percent to close at $7.00.
Xunlei Ltd (NASDAQ: XNET) shares rose 29.38 percent to close at $15.50 on Monday.
Blueprint Medicines Corp (NASDAQ: BPMC) gained 22.91 percent to close at $88.32 on Monday after the company announced new data from ongoing Phase 1 clinical trial of Avapritinib.
Overstock.com Inc (NASDAQ: OSTK) climbed 22.02 percent to close at $55.00 following 13G filing from Morgan Stanley late Friday showing increased stake from 130,000 shares to 2.87 million shares.
Clearside BioMedical, Inc. (NASDAQ: CLSD) shares jumped 19.69 percent to close at $7.05.
bluebird bio Inc (NASDAQ: BLUE) shares rose 17.91 percent to close at $201.80 after the company announced updated clinical results from ongoing Phase 1 multicenter study of LentiGlobin gene therapy in severe sickle cell disease at the ASH2017.
Chicken Soup for The Soul Entrtnmnt Inc (NASDAQ: CSSE) shares rose 17.04 percent to close at $9.48.
Social Reality Inc (NASDAQ: SRAX) shares jumped 16.96 percent to close at $6.00. Social Reality Inc announced late Friday a litigation settlement with tronc Inc and Tribune Content Agency over an alleged breach of contract and deceptive business practices. Social Reality also filed for 4,746,820 offering from selling shareholders.
Consol Energy Inc (NYSE: CEIX) shares rose 16.28 percent to close at $29.50 on Monday.
Intersect ENT Inc (NASDAQ: XENT) shares gained 14.51 percent to close at $32.75 as the company reported the FDA approval of SINUVA Sinus Implant as a treatment option for recurrent nasal polyps.
Shineco Inc (NASDAQ: TYHT) shares gained 12.77 percent to close at $2.9546 after the company disclosed a Share Exchange and Acquisition deal with Western Xinjiang Tiansheng Agricultural Development Co.
SunPower Corporation (NASDAQ: SPWR) rose 10.67 percent to close at $9.23. Baird upgraded SunPower from Neutral to Outperform.
CHF Solutions Inc (NASDAQ: CHFS) shares rose 10.59 percent to close at $3.80 on Monday after climbing 11.00 percent on Friday.
Catalyst Biosciences Inc (NASDAQ: CBIO) rose 10.21 percent to close at $8.31 as the company announced promising interim Phase 1/2 CB 2679D/ISU304 results at the ASH2017.
Helios and Matheson Analytics Inc (NASDAQ: HMNY) rose 8.05 percent to close at $9.13 following news of a new marketing and performance-based sales deal with a movie distributor.
Trade Desk Inc (NASDAQ: TTD) gained 6.74 percent to close at $48.30. SunTrust Robinson Humphrey upgraded Trade Desk from Hold to Buy.

Losers

Spark Therapeutics Inc (NASDAQ: ONCE) shares tumbled 34.97 percent to close at $47.72 on Monday on volatile factor VIII activity data in hemophilia A gene therapy.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) dipped 31.69 percent to close at $8.45 following presentation at the ASH 2017 on Phase 2 trial of SY-1425 in genomically defined AML and MDS patients.
Technical Communications Corporation (NASDAQ: TCCO) shares dropped 21.26 percent to close at $5.00 on Monday. Technical Communications reported a Q4 loss of $0.28 per share on revenue of $1.125 million.
Wins Finance Holdings Inc (NASDAQ: WINS) shares declined 18.66 percent to close at $47.02.
Verastem Inc (NASDAQ: VSTM) shares fell 16.86 percent to close at $3.60 after the company announced clinical data from the pivotal Phase 3 DUO study.
Athenex Inc (NASDAQ: ATNX) shares dropped 16.3 percent to close at $13.37. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.
Long Island Iced Tea Corp (NASDAQ: LTEA) shares fell 15.59 percent to close at $1.70.
bebe stores, inc. (NASDAQ: BEBE) shares dipped 15.08 percent to close at $4.73. Bebe stores announced intention to voluntarily delist from the NASDAQ and begin trading on OTCQB.
Juno Therapeutics Inc (NASDAQ: JUNO) declined 14.34 percent to close at $50.24. Juno Therapeutics and Celgene released additional data from the TRANSCEND trial of JCAR017 in patients with relapsed or refractory aggressive B-cell non-hodgkin lymphoma.
Co-Diagnostics Inc (NASDAQ: CODX) shares fell 13.64 percent to close at $3.80.
Trillium Therapeutics Inc (NASDAQ: TRIL) shares dropped 13.33 percent to close at $9.75 on Monday.
Arsanis Inc (NASDAQ: ASNS) shares declined 12.53 percent to close at $12.22 on Monday.
Novan Inc (NASDAQ: NOVN) shares slipped 11.16 percent to close at $4.30.
Ovid Therapeutics Inc (NASDAQ: OVID) shares dropped 10.99 percent to close at $10.45.
Hornbeck Offshore Services, Inc. (NYSE: HOS) shares slipped 10.86 percent to close at $2.79.
Anavex Life Sciences Corp (NASDAQ: AVXL) shares fell 10.57 percent to close at $3.30. Anavex Life Sciences reported FY17 loss of $0.33 per share, versus a year-ago loss of $0.42 per share.
Seattle Genetics, Inc. (NASDAQ: SGEN) shares declined 6.74 percent to close at $ 55.265. Seattle Genetics highlighted five-year survival results from Phase 1 trial of ADCETRIS in frontline mature T-cell lymphoma at the ASH 2017.